AstraZeneca Acquires Asian Rights To Cubist's Antibiotic Cubicin
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca acquired Asian rights to Cubist's antibiotic Cubicin (daptomycin), but the deal does not include Japan, Cubist announced Dec. 4
You may also be interested in...
Cubicin Indication Expands To Cover S. Aureus Bacteremia
Cubist says daptomycin injection is the only IV antibiotic approved for S. aureus bloodstream infections.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).